Psilocybin-Research.comSearchable psilocybin and psilocin bibliometrics.
CLINICAL TRIAL

Safety and Efficacy of Psilocybin for the Treatment of Headache Disorders: Sub-Study II

The purpose of this study is to investigate the effects of oral psilocybin in post-traumatic headache. Subjects will be randomized to receive placebo, low dose psilocybin, or high dose psilocybin on two separate test days approximately 14 days apart. Subjects will maintain a headache diary prior to, during, and after the treatments in order to document headache frequency and intensity, as well as associated symptoms. Blood samples will be drawn at various timepoints to measure levels of inflammatory peptides.

Open source BibTeX RIS

Bibliographic context

Journal
ClinicalTrials.gov
Date
2023-10-11
Source
ClinicalTrials.gov
DOI
Unavailable
PubMed
Unavailable

Authors

Yale University
Watch author

Topics and keywords

psilocybin Headache / MigraineSafetyInflammation Clinical Trial Post-Traumatic HeadachePlacebo oral capsuleLow Dose PsilocybinHigh Dose PsilocybinTERMINATED

Citation graph

0 referenced DOIs found in stored source metadata. 0 indexed papers cite this DOI.

Open citation network

Related papers

Psilocybin restores behavior and 5-HT2A signaling while reducing microglial density after chronic traumatic brain injury in ratsCell Reports Medicine · 2026-05-31Psilocybin-Assisted Therapy in Depressive Disorders: Efficacy, Safety, and Persistence of Clinical Effects - A Narrative ReviewJournal of Education Health and Sport · 2026-05-06Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentBiomolecules · 2026-07-02Psilocybin as a Transdiagnostic Treatment for Eating Disorders and Comorbid Psychopathology: Implications for Clinical Nosology and Research Directions.International Journal of Eating Disorders · 2026-07-01Study Protocol for "Exploring the safety and therapeutic potential of psilocybin in the treatment of anorexia nervosa in adolescents and young adults".PLoS ONE · 2026-06-29Naturally Derived Psilocybin for Therapeutic Use: A Six-Criterion Framework for Evidence, Safety, and Benefit-Risk Considerations in Policy and Clinical DevelopmentUniversity of Groningen research database (University of Groningen / Centre for Information Technology) · 2026-06-28Psilocybin-assisted therapy in treatment-resistant depression: rapid remission, uncertain durability, and the next phase of clinical evidenceAnnals of Medicine and Surgery · 2026-06-17DESI-MSI-Based Multi-Organ Distribution Mapping of Psilocin in ZebrafishMolecules · 2026-06-17